The Amedica Corporation recently released the results of its 24-month level 1 trial for the CASCADE composite silicon nitride fusion device...
Read More
CRE treatment to be developed, sold by Allergan, AstraZeneca
Allergan plc and AstraZeneca ink a global agreement to develop and commercialize ATM-AVI, an investigational fixed-dosed combination antibiotic, aztreonam and avibactam, for the treatment of serious infections caused by metallo-beta-lactamase (MBL)-producing Gram-negative bacteria, a difficult-to-treat subtype of carbapenem-resistant Enterobacteriaceae for which there are limited treatment options.
Read More